ADAR1 Capital Management LLC Sells 12,000 Shares of MoonLake Immunotherapeutics $MLTX

Key Points

• ADAR1 Capital Management LLC has significantly reduced its stake in MoonLake Immunotherapeutics by 68.9%, now holding shares worth $212,000.
• Several institutional investors have increased their investments in MoonLake, with Paradigm Biocapital Advisors LP raising its holdings by 90.3% during the last quarter.
• MoonLake Immunotherapeutics reported a quarterly loss with an EPS of ($0.87), missing estimates, while analysts project a consensus target price of $74.43 for the stock.

ADAR1 Capital Management LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 68.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,424 shares of the company's stock after selling 12,000 shares during the quarter. ADAR1 Capital Management LLC's holdings in MoonLake Immunotherapeutics were worth $212,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Paradigm Biocapital Advisors LP grew its stake in MoonLake Immunotherapeutics by 90.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,772,211 shares of the company's stock valued at $95,965,000 after acquiring an additional 840,731 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in MoonLake Immunotherapeutics by 9.4% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,434,770 shares of the company's stock valued at $56,056,000 after acquiring an additional 123,151 shares in the last quarter. Polar Capital Holdings Plc grew its stake in MoonLake Immunotherapeutics by 120.0% during the 4th quarter. Polar Capital Holdings Plc now owns 1,100,000 shares of the company's stock valued at $59,565,000 after acquiring an additional 600,000 shares in the last quarter. Fred Alger Management LLC grew its stake in shares of MoonLake Immunotherapeutics by 1.1% in the 4th quarter. Fred Alger Management LLC now owns 673,773 shares of the company's stock valued at $36,485,000 after buying an additional 7,199 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 1st quarter valued at approximately $26,308,000. Hedge funds and other institutional investors own 93.85% of the company's stock.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX traded up $0.12 during mid-day trading on Monday, hitting $59.56. The company's stock had a trading volume of 216,798 shares, compared to its average volume of 485,831. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $61.87. The company has a debt-to-equity ratio of 0.21, a quick ratio of 16.65 and a current ratio of 16.65. The firm has a market capitalization of $3.83 billion, a PE ratio of -21.45 and a beta of 1.27. The stock's 50-day moving average is $52.89 and its two-hundred day moving average is $44.66.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same quarter in the prior year, the company earned ($0.39) earnings per share. As a group, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on MLTX shares. Redburn Atlantic raised MoonLake Immunotherapeutics to a "hold" rating in a research note on Monday, July 28th. The Goldman Sachs Group boosted their price target on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Needham & Company LLC reissued a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Rothschild & Co Redburn started coverage on MoonLake Immunotherapeutics in a research note on Monday, July 28th. They issued a "neutral" rating and a $65.00 price target for the company. Finally, Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target for the company in a research note on Monday, May 19th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $74.43.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.